An update from Wave Life Sciences ( (WVE) ) is now available.
On March 4, 2025, Wave Life Sciences announced its financial results for the fourth quarter and full year of 2024, alongside a business update. The company highlighted progress in its clinical trials, including the INLIGHT trial for obesity and the RestorAATion-2 trial for alpha-1 antitrypsin deficiency. They also reported advancements in their RNA editing and exon skipping programs, with significant milestones expected in 2025. The company maintains a strong cash position, ensuring operational runway into 2027, and continues to build its pipeline targeting high-impact biology.
More about Wave Life Sciences
Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing RNA medicines to transform human health.
YTD Price Performance: -20.65%
Average Trading Volume: 913,631
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.61B
See more insights into WVE stock on TipRanks’ Stock Analysis page.